TransEnterix (NYSE:TRXC) said today it is looking to expand the use of its Senhance robotic surgical system to include hernia repair surgeries, touting that the system has been used in for the 1st time in such procedures in Germany.
Research Triangle Park, N.C.-based Transenterix said that Dr. Dietmar Stephan and Dr. Frank Willeke performed up to 3 hernia surgeries with the robotic platform per day during the system’s 1st weeks of clinical use at the St. Marien-Krankenhaus Siegen hernia repair center in Germany.
“We are pleased to offer robotic hernia repair utilizing the Senhance Robotic System, and all our operations utilizing this advanced technology have been performed with precision, safety and efficiency. The 3D visualization and precise control of the robotic instruments and camera are very helpful during delicate surgical tasks. The haptic feedback of the system is vital, and it allows me to feel the location of critical structures such as the pubic bone which aren’t always visible. The Senhance is a significant progression in the field of minimally invasive hernia repair, and allows me to fully incorporate robotics into my hernia practice without having to justify high additional procedural costs,” Dr. Dietmar Stephan of Germany’s St. Marien-Krankenhaus Siegen said in a press release.
The St. Marien-Krankenhaus Siegen center picked up one of the robotic platforms last month, the company reported, making it the 1st sale of the system in Germany. The hospital said it will use the device to establish a robotic surgical program that will initially focus on general and gynecologic surgery.
“Robotic hernia repair with the Senhance system represents a significant procedural area for our technology. Hernia repairs, both inguinal and ventral, are amongst the most common surgical procedures performed worldwide. These procedures also represent one of the fastest growing uses of robotics in surgery. The introduction of Senhance to provide robotic assistance in these procedures brings a system with haptic feedback and attractive procedural costs to these operations for the first time,” CEO Todd Pope said in a prepared statement.
Earlier in February, TransEnterix touted the 1st clinical use of its Senhance robot-assisted surgery platform in France
The 1st French case, performed by Dr. Celine Chauleur of CHU Saint-Ètienne, was a hysterectomy to treat endometrial cancer with pelvic lymphadenectomy Feb. 7. The patient was discharged less than 24 hours after surgery, Morrisville, N.C.-based TransEnterix said.